2016-2017 NARMS Integrated Summary | FDA

2016-2017 NARMS Integrated Summary | FDA

Report Summarizes 2016–2017 NARMS Data from FDA, CDC, and USDA

A new report is available from the National Antimicrobial Resistance Monitoring System (NARMS) for enteric bacteria. The 2016-2017 NARMS Integrated Summary was released by the U.S. Food and Drug Administration with its NARMS partners, CDC and the U.S. Department of Agriculture’s Food Safety and Inspection Service. The report’s new streamlined format will enable NARMS partners to provide more timely public updates. .

Included in this report for the first time: Veterinary data on pathogens affecting animals. Genomic information for Campylobacter and E. coli isolates from retail meat and food animals. Until now, this information was only available for Salmonella. Some notable observations from the 2016–2017 NARMS data include: Salmonella resistance to third-generation cephalosporins, fluoroquinolones, or azithromycin has increased. Information about sources is available in the report. This increase is concerning as these drugs are considered first-line therapies to treat complicated infectious diarrhea in humans. The rise in Salmonella resistance to these drugs means that treatment with them might not always work No resistance to carbapenems was observed among Salmonella isolates from humans, retail meats, and animals. This is important as carbapenems are used for severe multidrug-resistant infections.